Esper and Lenovo Collaborate on Android Device Deployment in Enterprises
21.10.2021 16:05:00 EEST | Business Wire | Press release
DevOps for Devices leader Esper and Lenovo™ are teaming up to place Esper software on key models of Lenovo Android tablets and other intelligent business devices. This collaboration allows enterprises that manage large fleets of devices to focus on their critical line-of-business applications, leaving the device infrastructure and management tasks to Lenovo and Esper’s joint solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005372/en/
Lenovo K10 Tablet (Photo: Business Wire)
As the fastest-growing tablet maker (YoY) last quarter1, Lenovo’s expertise in smarter device design, engineering and user experiences combines with Esper’s modern, DevOps-powered device infrastructure software that lets organizations of every size and segment (e.g. healthcare, retail, hospitality), easily set up, manage, better secure, and maintain large fleets of devices on their journey to digital transformation.
“With proprietary features like real-time telemetry and seamless provisioning, organizations across industries can rely on Esper to provide cutting-edge solutions that are flexible enough to grow with scaling enterprise fleets,” said Tony Chen, vice president of Lenovo’s Android Tablet Business, Intelligent Devices Group. “Lenovo is committed to nurturing an open ecosystem that encourages third-party developers to create software for its devices at scale – together, Esper and Lenovo are providing the infrastructure plus ongoing support needed to innovate in the Android edge space.”
Esper and Lenovo already have joint wins in food delivery, hospitality and healthcare verticals. Their joint solution has provided global customers a more reliable infrastructure to accelerate their device deployment leading to significant revenue growth.
The new Lenovo-Esper partnership will target market segments like healthcare in which devices used by consumers and practitioners alike have very high requirements for reliability, ease of use, and up-to-date security and privacy software. Legacy mobile device management (MDM) solutions do not yet support healthcare providers’ need to deploy and maintain advanced software enterprises. By combining Esper’s infrastructure with Lenovo’s state-of-the-art tablets, healthcare providers can now have the tools they need for a seamless customer experience for their patients.
“Esper is proud to be recognized as a longtime collaborator by Lenovo. We share a vision of being valued solutions providers to customers around the globe. Esper’s infrastructure platform fits perfectly into Lenovo’s Android device ecosystem. Together, we’re simplifying the management and platform so customers can focus on their core strengths – their application. We applaud Lenovo’s commitment to industry collaboration as the fuel for their vision to enable ‘smarter technology for all,’” commented Shiv Sundar, Esper co-founder and COO.
Esper is the leader in DevOps software in the intelligent edge device space. The company recently announced that it has raised over $100 million dollars in top-tier venture funding. This financial strength allows them to aggressively innovate their device infrastructure platform in partnership with innovation leaders like Lenovo.
About Esper
Esper offers a DevOps SaaS platform for intelligent edge devices. As the industry’s leading solution for Android DevOps, Esper is on a mission to let software teams ship without worrying about the hardware. Esper’s device infrastructure enables developers, mid-market organizations, and enterprise fleets of 100,000+ devices to deliver their software as a service. Esper has rapidly-growing global customer adoption among some of the world’s most innovative major brands in retail, hospitality, logistics, healthcare, education and more. For more information visit: https://esper.io.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.
1 Based on IDC’s 2021 (2Q21) data for year-over-year growth
LENOVO is a trademark of Lenovo. Android is a trademark of Google, LLC. All other trademarks are the property of their respective owners. ©2021, Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005372/en/
Contact information
Emily Carrion
206-660-3304
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 09:00:00 EEST | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This facility was secured prior to IQM’s recent announcement of plans to become the first publicly listed European quantum computing company through a merger with Real Asset Acquisition Corp (“RAAQ”). The facility lowers IQM’s overall cost of capital and improves the flexibility and diversity of its capital base. “The financing package comes at a pivotal time for IQM, as we build momen
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 08:45:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom